Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; GDNF therapy; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; MSC-NTF; Neurotrophic factor-secreting stem cell therapy; NurOwn; NurOwn™ program one

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Autistic disorder; Huntington's disease; Multiple sclerosis; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 19 Apr 2017 Preclinical data in Autistic disorder released by BrainStorm Cell Therapeutics
  • 19 Dec 2016 BrainStorm Cell Therapeutics plans a phase III trial for Amyotrophic lateral sclerosis in USA and Israel
  • 19 Dec 2016 Brainstorm Cell Therapeutics intends to submit for Hospital exemption in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top